CGI's Proprietary DNA-Based Test for Cervical Cancer, FHACT(TM), Adopted by Leading Kamineni Hospital Group in India for the Diagnosis and Triaging of Cervical Cancer

  • There are over 123,000 new cervical cancer cases in India each year where it is a leading cause of cancer mortality, causing 17% of deaths in women 30-69 years of age.
  • Adoption of FHACT™ cervical cancer test by Kamineni Hospitals positions CGI to significantly improve women's health in India.

RUTHERFORD, N.J., March 20, 2014 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company"), an emerging leader in DNA-based diagnostics, announced today that Kamineni Hospitals based in Hyderabad, India, have introduced CGI's FHACT™ diagnostic test for the detection and management of cervical cancer. This is the first broad-scale adoption of the genomic test in India where cervical cancer is the most prevalent cancer affecting women.

CGI's FISH-Based HPV-Associated Cancer Test (FHACT™) assesses genomic alterations commonly observed in cervical pre-cancer and cancer upon infection and persistence of HPV. FHACT™ is a unique DNA FISH probe combination of four genomic biomarkers that can be used on remnant liquid Pap cytology or on conventional Pap smear.

Cervical cancer is the most common cancer affecting women in India, where cervical cancer contributes to 20-30% of total global incidence.1 In 2012, there were roughly 528,000 new cases diagnosed worldwide, 123,000 of them in India.2 Due to the prevalence and ongoing growth of cervical cancer in India, the adoption of FHACT™ by Kamineni represents a major opportunity to improve women's health and potentially improve patient outcomes. This launch culminates a collaboration begun in July of 2013 to assess the value and clinical utility of FHACT™ in India.

Panna Sharma, President and CEO of CGI, stated, "Kamineni is a leading hospital system in India and a model for the future health enterprise where they bring together physicians, researchers and world-class facilities to aggressively pursue solving and managing serious health conditions."

Cervical cancer mortality rates in India remain high due to late screening and a lack of effective screening programs. Kamineni Hospitals will be offering the test in conjunction with Pap smear and HPV testing, and believes that the test will allow for more wide-spread, early detection of cervical cancer. CGI's FHACT™ test doesn't require additional patient visits to the doctor or laboratory and offers a significant advantage for predominantly rural populations in India and other developing countries, where access to healthcare providers is limited. CGI is actively pursuing and seeking additional collaborations in high growth, developing economies where managing cervical cancer is a primary health concern.

FHACT™ is a unique combination of four genomic biomarkers that can be used on remnant liquid pap cytology or on conventional Pap smear. In the U.S. the test is offered in CGI's CLIA laboratory in New Jersey and is intended to help in the triaging associated with the diagnosis and management of the approximately 3.5 million abnormal Pap smears in the U.S.

About Cancer Genetics:

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company's Form 10-Q for the quarter ended September 30, 2013 and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.



CONTACT: Investor Relations Michael Rice Life Science Advisors LLC 646-597-6979 Media Relations RedChip Companies, Inc. Paul Kuntz, 800-733-2447, ext. 105 paul@redchip.comSource:Cancer Genetics